Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.

ABSTRACT:

Background

Alterations in fibroblast growth factor receptor 3 (FGFR3) occur in ∼15% of muscle-invasive bladder cancers (MIBCs) and metastatic urothelial carcinomas (mUCs).

Objective

To determine the association between FGFR3 status and response to platinum-based chemotherapy in patients with MIBC or mUC.

Design, setting, and participants

The authors conducted a retrospective review and comparison of patients having (1) MIBC treated with neoadjuvant chemotherapy (NAC), (2) mUC treated with first-line platinum-based chemotherapy (M1 cohort), and (3) MIBC who were from The Cancer Genome Atlas (TCGA).

Intervention

Platinum-based chemotherapy.

Outcome measurements and statistical analysis

Pathologic response, recurrence-free (RFS) or progression-free (PFS) su

SUBMITTER: Teo MY 

PROVIDER: S-EPMC8215618 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature